United States - English - NLM (National Library of Medicine)

bela vida holdings, llc dba body time - avobenzone 3.0%, octinoxate 7.5%, octisalate 5.0%, oxybenzone 4.0% - sunscreen - helps prevent sunburn. - if used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skin aging caused by the sun.

United States - English - NLM (National Library of Medicine)

bela vida holdings, llc dba body time - avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y) - - helps prevent sunburn - if used as directed with other sun protection measures (see directions), decrease the risk of skin cancer and early skin aging caused by the sun.

United States - English - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - belatacept (unii: e3b2gi648a) (belatacept - unii:e3b2gi648a) - belatacept 250 mg - nulojix® (belatacept) is indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant. nulojix is to be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids. use nulojix only in patients who are ebv seropositive [see contraindications (4) and warnings and precautions (5.1)] . use of nulojix for the prophylaxis of organ rejection in transplanted organs other than kidney has not been established [see warnings and precautions (5.6)] . nulojix is contraindicated in transplant recipients who are epstein-barr virus (ebv) seronegative or with unknown ebv serostatus due to the risk of post-transplant lymphoproliferative disorder (ptld), predominantly involving the central nervous system (cns) [see boxed warning and warnings and precautions (5.1)] . to monitor maternal-fetal outcomes of pregnant women who have received immunosuppressants including nulojix or whose partners have received nulojix, healthcare providers are strongly encouraged to regis

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - belatacept, quantity: 250 mg - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid; monobasic sodium phosphate; sucrose; nitrogen; sodium hydroxide; sodium chloride - nulojix (belatacept) is indicated for prophylaxis of organ rejection in adults receiving a renal transplant. nulojix is to be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids.

Israel - English - Ministry of Health

tec-o-pharm-libra ltd - chlormadinone acetate; ethinylestradiol - film coated tablets - ethinylestradiol 0.03 mg; chlormadinone acetate 2 mg - etynodiol and estrogen - etynodiol and estrogen - oral hormonal contraceptive.

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - immunosuppressants - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant. 

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pahang pharmacy sdn. bhd. - chlormadinone acetate; ethinylestradiol -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - belatacept - powder for solution for infusion - 250mg